Surgepays is trading at $0.31 (6.2% down) as investors weigh the impact of a recent underwritten public offering and potential share dilution.
- The stock is facing additional pressure from Nasdaq noncompliance, which has heightened delisting risks.
- Market sentiment remains negative, extending the selloff triggered by the company's capital raise announcement.